<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Occupational asthma: Clinical features, evaluation, and diagnosis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Occupational asthma: Clinical features, evaluation, and diagnosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Occupational asthma: Clinical features, evaluation, and diagnosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Catherine Lemière, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David I Bernstein, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Hille Suojalehto, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter J Barnes, DM, DSc, FRCP, FRS</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul Dieffenbach, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 17, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Occupational asthma (OA) is a form of work-related asthma characterized by variable airflow obstruction, airway hyperresponsiveness, and airway inflammation attributable to exposures in the workplace and not due to stimuli encountered outside the workplace [<a href="#rid1">1</a>]. Work-exacerbated asthma (also known as work-aggravated asthma) is defined as preexisting or concurrent asthma that subjectively worsens in the workplace.</p><p>The clinical features, evaluation, and diagnosis of suspected sensitizer-induced OA will be reviewed here. The pathophysiology, epidemiology, causes, risk factors, and management of OA and reactive airways dysfunction syndrome are discussed separately. (See  <a class="medical medical_review" href="/d/html/538.html" rel="external">"Occupational asthma: Pathogenesis"</a> and  <a class="medical medical_review" href="/d/html/537.html" rel="external">"Occupational asthma: Definitions, epidemiology, causes, and risk factors"</a> and  <a class="medical medical_review" href="/d/html/15718.html" rel="external">"Occupational asthma: Management, prognosis, and prevention"</a> and  <a class="medical medical_review" href="/d/html/2749.html" rel="external">"Overview of occupational and environmental health"</a> and  <a class="medical medical_review" href="/d/html/536.html" rel="external">"Irritant-induced asthma"</a>.)</p><p class="headingAnchor" id="H4122937834"><span class="h1">CLINICAL FEATURES</span></p><p class="headingAnchor" id="H5063656"><span class="h2">Lower respiratory symptoms</span><span class="headingEndMark"> — </span>The typical symptoms of OA are the same as nonoccupational asthma and include cough, sputum production, dyspnea, wheeze, and chest tightness. (See  <a class="medical medical_review" href="/d/html/543.html" rel="external">"Asthma in adolescents and adults: Evaluation and diagnosis", section on 'Clinical features'</a>.)</p><p>Some patients report a pattern of increased symptoms while at work or within several hours of the completion of a work shift and improvement on weekends or during vacations, but this is variable. (See <a class="local">'Time course'</a> below.)</p><p>Once sensitized, workers exposed to high molecular weight (HMW) agents are more likely to report early (eg, within an hour of workplace exposure) asthmatic reactions [<a href="#rid2">2,3</a>]. In contrast, workers exposed to low molecular weight (LMW) agents are more likely to experience late asthmatic reactions, chest tightness at work, daily sputum production, and a higher risk of severe exacerbations [<a href="#rid3">3</a>]. The delay in symptom onset with LMW agents may reflect mediation by a non-immunoglobulin E (IgE) mechanism. (See  <a class="medical medical_review" href="/d/html/537.html" rel="external">"Occupational asthma: Definitions, epidemiology, causes, and risk factors", section on 'Causative agents'</a>.)</p><p class="headingAnchor" id="H5064099"><span class="h2">Extrapulmonary symptoms</span><span class="headingEndMark"> — </span>Certain patterns of extrapulmonary symptoms are strongly associated with OA, although they are not sufficiently specific to secure a diagnosis or cause of OA.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rhinoconjunctivitis</strong> – Symptoms of work-related rhinoconjunctivitis (itchy eyes, tearing, sneezing, nasal congestion, rhinorrhea) often precede symptoms of OA caused by HMW proteinaceous agents [<a href="#rid3">3-7</a>], or may accompany symptoms of OA caused by other HMW agents and the LMW agents [<a href="#rid8">8</a>]. In general, workers with HMW-inducer OA are more likely to report occupational rhinitis (odds ratio [OR] 4.79, 95% CI 3.28-7.12) or conjunctivitis (OR 2.13, 95% CI 1.52-2.98), compared with those with LMW-inducer OA, and their symptoms are often more severe. (See  <a class="medical medical_review" href="/d/html/7529.html" rel="external">"Occupational rhinitis"</a>.)</p><p></p><p class="bulletIndent1">The report of work-related wheezing, nasal symptoms, and ocular itching substantially increases the likelihood of OA, especially among workers exposed to HMW agents [<a href="#rid8">8</a>]. However, these symptoms are not predictive in subjects exposed to LMW agents. (See  <a class="medical medical_review" href="/d/html/537.html" rel="external">"Occupational asthma: Definitions, epidemiology, causes, and risk factors", section on 'Causative agents'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Allergic contact dermatitis</strong> – Several agents that cause OA (eg, diisocyanates, epoxies, rubber accelerant chemicals in latex, or cleaning agents) have been associated with allergic contact dermatitis [<a href="#rid9">9-16</a>]. However, the occurrence of contact dermatitis is generally not predictive of OA [<a href="#rid17">17</a>]. (See  <a class="medical medical_review" href="/d/html/13656.html" rel="external">"Common allergens in allergic contact dermatitis"</a> and  <a class="medical medical_review" href="/d/html/13655.html" rel="external">"Clinical features and diagnosis of allergic contact dermatitis"</a>.)</p><p></p><p class="bulletIndent1">An exception comes from a study of adolescent car painting apprentices (exposed to diisocyanates) in which occupational dermatitis was predictive of work-related asthma symptoms [<a href="#rid9">9</a>]. Cobalt exposure has also been associated with the combination of OA and contact dermatitis [<a href="#rid14">14</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Urticaria</strong> – Work-related urticaria on exposed body parts is sometimes seen with exposure to HMW agents such as latex, mammalian proteins from furry animals, or crustaceans (eg, crab) and may suggest an IgE-mediated process, but there are no studies looking at its predictive value for the development of OA. (See  <a class="medical medical_review" href="/d/html/8108.html" rel="external">"Chronic spontaneous urticaria: Clinical manifestations, diagnosis, pathogenesis, and natural history"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hoarseness</strong> – Questionnaires are poorly specific in diagnosing OA. However, among symptoms reported by workers referred for possible OA, wheezing, nasal, and ocular itching at work were positively, and loss of voice negatively, associated with the presence of OA in the case of HMW, but not LMW agents [<a href="#rid8">8</a>].</p><p></p><p class="headingAnchor" id="H86045157"><span class="h2">Physical examination</span><span class="headingEndMark"> — </span>The physical examination in OA is generally nonspecific and may be normal during office visits away from the occupational exposure. Widespread, high-pitched wheezes are characteristic of asthma, heard most commonly on expiration, but sometimes also during inspiration. However, the presence or absence of wheezing on physical examination is a poor predictor of the presence or severity of OA. (See  <a class="medical medical_review" href="/d/html/543.html" rel="external">"Asthma in adolescents and adults: Evaluation and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/543.html" rel="external">"Asthma in adolescents and adults: Evaluation and diagnosis", section on 'Physical findings'</a>.)</p><p>Patients with OA may also have pale, swollen nasal mucosa, suggesting concomitant occupational rhinitis [<a href="#rid18">18</a>]. (See  <a class="medical medical_review" href="/d/html/7529.html" rel="external">"Occupational rhinitis"</a>.)</p><p>Rarely, an erythematous, eczematous rash (consistent with allergic contact dermatitis) or urticarial rash may be present on skin exposed to the sensitizing agent in the workplace. (See  <a class="medical medical_review" href="/d/html/13655.html" rel="external">"Clinical features and diagnosis of allergic contact dermatitis"</a>.)</p><p class="headingAnchor" id="H1910505870"><span class="h1">EVALUATION</span><span class="headingEndMark"> — </span>OA should be suspected in every adult with new onset asthma, as OA accounts for approximately 10 to 16 percent of adult onset asthma with some between study variability [<a href="#rid19">19-21</a>]. Patients with reappearance of childhood asthma and deteriorating asthma control on stable therapy should also be screened for OA [<a href="#rid22">22</a>]. For all patients, the evaluation begins with an occupational history, focused on known or potential sensitizing agents. Our approach to testing combines complementary tests, as individual tests have limitations when viewed in isolation. The approach differs if patients are still working and exposed to causative substances  (<a class="graphic graphic_algorithm graphicRef138428" href="/d/graphic/138428.html" rel="external">algorithm 1</a>) or are no longer working  (<a class="graphic graphic_algorithm graphicRef138427" href="/d/graphic/138427.html" rel="external">algorithm 2</a>). (See  <a class="medical medical_review" href="/d/html/537.html" rel="external">"Occupational asthma: Definitions, epidemiology, causes, and risk factors", section on 'Epidemiology'</a>.)</p><p class="headingAnchor" id="H2532216470"><span class="h2">Occupational history</span><span class="headingEndMark"> — </span>The onset of symptoms relative to exposure varies and a work-related association may not be spontaneously reported by the patient. Thus, the clinical history in patients with possible OA should include detailed questioning about the job description and potential exposures to causal agents, in addition to the routine evaluation of adult-onset asthma  (<a class="graphic graphic_table graphicRef122138" href="/d/graphic/122138.html" rel="external">table 1</a>) [<a href="#rid23">23,24</a>]. The clinical history, while important, is not sufficient to confirm or exclude the diagnosis of OA [<a href="#rid25">25-27</a>]. (See  <a class="medical medical_review" href="/d/html/543.html" rel="external">"Asthma in adolescents and adults: Evaluation and diagnosis"</a>.)</p><p class="headingAnchor" id="H1851291957"><span class="h3">Exposures</span><span class="headingEndMark"> — </span>All adults with asthma should be questioned not only about their current occupation and exposures, but also about their previous occupations and exposures  (<a class="graphic graphic_table graphicRef66185" href="/d/graphic/66185.html" rel="external">table 2</a>). Once the patient’s occupation is ascertained, the potential associated exposures can be evaluated in greater detail. Asking about exposure to vapors, gas, fumes, or dust may help the patient’s recall [<a href="#rid28">28</a>]. </p><p>As examples, the job description of "engineer" or "clerk" does not yield a full account of the actual exposures in the workplace. Further questioning may reveal indirect exposure to a sensitizing agent depending upon the particular work environment (eg, a work station adjacent to the paint booth in an auto body shop, desk near the site of the flood in an office building, work space adjacent to packaging area in epoxy paint factory). Janitorial and healthcare work may involve use of amines or bleach in cleaning. Exposure to cigarette smoke (active or passive) can occur in many occupations and may trigger symptoms on an irritant basis.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Occupation-specific exposures</strong> – Certain industries or professions are associated with greater contact with agents that have a high potential for provoking OA [<a href="#rid29">29</a>]. As examples, nurses may be exposed to <a class="drug drug_general" data-topicid="9834" href="/d/drug information/9834.html" rel="external">psyllium</a>, <a class="drug drug_general" data-topicid="9244" href="/d/drug information/9244.html" rel="external">chlorhexidine</a>, pharmaceutical products, enzymes, glutaraldehyde, or formaldehyde, while spray painters may be exposed to diisocyanates, acrylates, and various amines  (<a class="graphic graphic_table graphicRef66185" href="/d/graphic/66185.html" rel="external">table 2</a>). A description of the more common causative agents and their associated occupations is provided separately. (See  <a class="medical medical_review" href="/d/html/537.html" rel="external">"Occupational asthma: Definitions, epidemiology, causes, and risk factors", section on 'Causative agents'</a>.)</p><p></p><p class="bulletIndent1">Additional information on agents that cause OA is available at <a class="external" href="/external-redirect?target_url=https%3A%2F%2Freptox.cnesst.gouv.qc.ca%2Fen%2Foccupational-asthma%2Fpages%2Foccupational-asthma.aspx&amp;token=S%2BdALU4MZZ8m3s4uoi5yqIb6aEuYweSj5D0AFSn9NsuyvE0zfLaSwgPP9JtQoK2YM%2F43lA6qCA74KBh7caLhiCL8Ivv%2BhchVH65j4XNKLo8%3D&amp;TOPIC_ID=550" target="_blank">https://reptox.cnesst.gouv.qc.ca/en/occupational-asthma/Pages/occupational-asthma.aspx</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Safety data sheet (SDS)</strong> – When OA is suspected, but the exact cause is unclear, it is important to obtain a list of the potential causative agents used by the worker or in the workplace. If the names of the chemicals in the workplace are not known, the worker can obtain the SDS from the employer. In the United States, the Occupational Safety and Health Administration (OSHA) requires that suppliers include a SDS with each shipment of an industrial material or chemical, and workers are entitled to receive copies of these sheets.</p><p></p><p class="bulletIndent1">Importantly, one should not depend entirely upon the information present in safety data sheets, because regulations stipulate that materials present in concentrations less than 1 percent need not be reported and high molecular weight (HMW) compounds from animal and plant sources are typically omitted [<a href="#rid30">30</a>]. In addition, careful review is needed in case an alternate name for a chemical of interest is used, such as urethane or polyester instead of diisocyanate.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nonspecific irritants</strong> – Asking about exposure to nonspecific irritants (eg, environmental tobacco smoke, strong fumes, extremes of temperature and humidity) is important as all types of asthma can be worsened by exposure to nonspecific irritants at work, a condition that is labeled work-exacerbated asthma [<a href="#rid31">31</a>]. This sensitivity to nonspecific irritants is particularly likely among patients who are exposed to chemical products such as ammonia, engine-exhaust fuel, aerosols and solvents [<a href="#rid32">32</a>], have severe airway (bronchial) hyperresponsiveness, and/or are undertreated with medication. (See  <a class="medical medical_review" href="/d/html/537.html" rel="external">"Occupational asthma: Definitions, epidemiology, causes, and risk factors", section on 'Definitions'</a>.)</p><p></p><p class="bulletIndent1">Few studies have investigated non-allergic irritant-induced asthma in which multiple irritant exposures at low concentrations appear to induce asthma in the absence of pre-existing asthma [<a href="#rid33">33</a>]. Since there is no specific testing that can prove that asthma has been caused by repetitive exposure to an irritant agent, it is often difficult to establish the diagnosis of irritant-induced asthma with certainty. However, epidemiologic studies suggest that some jobs, like cleaning and pulp mill work that are associated with exposure to high concentration of irritants, are associated with an increasing risk for the occurrence of asthma [<a href="#rid34">34</a>]. Irritant-induced asthma is discussed separately. (See  <a class="medical medical_review" href="/d/html/536.html" rel="external">"Irritant-induced asthma"</a>.)</p><p></p><p class="headingAnchor" id="H77178185"><span class="h3">Time course</span><span class="headingEndMark"> — </span>The natural history of immune-mediated OA is characterized by the following progression  (<a class="graphic graphic_figure graphicRef80111" href="/d/graphic/80111.html" rel="external">figure 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Onset of exposure</p><p class="bulletIndent1"><span class="glyph">●</span>Sensitization</p><p class="bulletIndent1"><span class="glyph">●</span>Onset of upper and lower airway inflammation</p><p class="bulletIndent1"><span class="glyph">●</span>Clinical disease</p><p class="bulletIndent1"><span class="glyph">●</span>Cessation or persistence of exposure</p><p class="bulletIndent1"><span class="glyph">●</span>Cure, improvement, or persistence of asthma</p><p></p><p>The latency period between the onset of exposure and the onset of symptoms is highly variable in OA, ranging from months to years. The latency period may vary according to the type of agent, being shorter with exposure to low molecular weight (LMW) agents, such as diisocyanates and plicatic acid (Western red cedar), than with HMW agents  (<a class="graphic graphic_table graphicRef66185" href="/d/graphic/66185.html" rel="external">table 2</a>) [<a href="#rid3">3,35</a>].</p><p>As an example, among 1179 OA patients, those exposed to HMW agents developed symptoms after a median of eight years of exposure compared with 5.1 years for those exposed to LMW agents [<a href="#rid3">3</a>]. The latency period also varies between HMW agents; sensitization to laboratory animals occurs more commonly and rapidly than sensitization to flour [<a href="#rid4">4</a>].</p><p>A pattern of increased symptoms while at work or within several hours of the completion of a shift, and a definite improvement on weekends or during vacations, is common in OA, but documenting this feature is not necessarily helpful. In a series of 162 patients referred for evaluation of possible OA, 88 percent of patients with confirmed OA stated that their symptoms improved during holidays, while 76 percent of patients without OA reported a similar improvement [<a href="#rid25">25</a>]. In addition, the absence of this pattern does not exclude the possibility of OA.</p><p>Workers with more advanced OA and those who are only away from work for brief intervals are less likely to report this classic pattern, possibly due to insufficient time away from work to allow improvement or a combination of early and late phase reactions that leads to persistent symptoms. (See  <a class="medical medical_review" href="/d/html/522.html" rel="external">"Pathogenesis of asthma", section on 'Early and late phase reactions'</a>.)</p><p>Furthermore, workers may not be exposed to the etiologic agent every day, and intermittent exposures make it difficult to relate symptoms to work.</p><p class="headingAnchor" id="H1951968951"><span class="h3">Atopy</span><span class="headingEndMark"> — </span>The possibility of pre-existing asthma and atopy (genetic predilection to produce specific immunoglobulin E (IgE) following exposure to allergens) should be explored in all patients with suspected occupational asthma. Thus, we ask patients about prior symptoms suggestive of asthma, allergic rhinitis, and atopic dermatitis. This information can help determine whether the patient has new onset disease or a pre-existing process that has worsened. (See  <a class="medical medical_review" href="/d/html/83038.html" rel="external">"The relationship between IgE and allergic disease"</a>.)</p><p>While atopy is an important individual risk factor for OA induced by HMW agents [<a href="#rid36">36</a>], atopy by itself has a poor positive predictive value for the presence of OA.</p><p class="bulletIndent1"><span class="glyph">●</span>Only approximately one-third of atopic subjects developed rhinoconjunctivitis or asthma symptoms in the five years following onset of exposure to laboratory animals [<a href="#rid37">37</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Because atopy is present in almost 50 percent of young adults, it alone does not satisfactorily predict the development of OA.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Furthermore, pre-existing asthma is not a predisposing factor for immunologic OA.</p><p></p><p class="headingAnchor" id="H2930296609"><span class="h2">Skin and immunologic testing</span><span class="headingEndMark"> — </span>Skin tests and immunoassays for serum specific IgE (ssIgE) have several roles in the evaluation of OA: they can identify sensitization to potential culprit allergens (when available); they can be used to identify sensitivity to common (nonoccupational) aeroallergens that can contribute to symptoms; and newer molecular methods may eventually improve the ability of testing to relate specific epitope sensitivity to the likelihood of disease.</p><p>The presence of immediate skin test reactivity or ssIgE reflects specific sensitization, but a positive result can be found in some patients without symptoms of asthma or rhinoconjunctivitis. Therefore, it is important to document objective evidence of physiological changes (eg, airflow obstruction, airway hyperresponsiveness, and/or increased sputum eosinophils) related to exposure, in addition to skin test reactivity or positive testing for specific IgE.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Skin prick test to common aeroallergens</strong> – Skin testing with a panel of common aeroallergens is often performed to identify nonoccupational allergens (eg, pets, pollen, dust mite) that may be contributing to the patient’s asthma. (See  <a class="medical medical_review" href="/d/html/5541.html" rel="external">"Overview of skin testing for IgE-mediated allergic disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Skin testing to potential culprit allergens</strong> – Skin test reagents for documenting hypersensitivity are only available for a few occupational agents. Extracts of HMW antigens, such as plant material (wheat), mold (<em>Alternaria</em>, <em>Cladosporium</em>), and animal proteins (laboratory animals, insects), have a sensitivity of 0.74 (95% CI 0.66-0.80) and a specificity of 0.71 (95% CI 0.63-0.77), while extracts of LMW agents have a much lower sensitivity and are less commonly available [<a href="#rid38">38,39</a>].</p><p></p><p class="bulletIndent1">Skin testing can be performed with extracts of HMW agents made in the clinic using material provided by the worker, but these extracts are not standardized and are not very specific or sensitive.</p><p></p><p class="bulletIndent1">Negative skin prick tests with HMW allergens (eg, relevant cereals, mites, and enzymes in a baker) virtually exclude the possibility that OA is caused by that specific antigen, provided that the skin testing extract reflects the actual exposure and is of the correct concentration to elicit a response [<a href="#rid19">19,27</a>]. (See  <a class="medical medical_review" href="/d/html/537.html" rel="external">"Occupational asthma: Definitions, epidemiology, causes, and risk factors", section on 'Combined exposures'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Serum specific IgE antibodies</strong> – In vitro immunoassay for IgE antibodies to occupational sensitizers is available for a limited number of HMW agents (eg, animal danders, latex, wheat) and LMW chemical-protein conjugates (eg, diisocyanates), but these are not standardized or not always commercially available [<a href="#rid19">19</a>]. When positive, they support but do not confirm the diagnosis of OA to that agent; furthermore, the sensitivity of this testing is low, particularly with LMW agents. (See  <a class="medical medical_review" href="/d/html/5540.html" rel="external">"Overview of in vitro allergy tests", section on 'Immunoassays for allergen-specific IgE'</a>.)</p><p></p><p class="bulletIndent1">Some LMW agents, such as platinum salts and trimellitic or phthalic anhydride, can be developed for skin testing, but these are usually not standardized and the sensitivity of testing is low  (<a class="graphic graphic_table graphicRef66185" href="/d/graphic/66185.html" rel="external">table 2</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Recombinant allergens and component resolved diagnosis</strong> – Component resolved diagnosis is an emerging molecular method for the diagnosis of OA and rhinitis [<a href="#rid40">40-43</a>]. It utilizes purified recombinant allergens to identify sensitization and characterize the specific allergens involved. It appears that IgE to certain allergenic moieties is more likely to be associated with a severe response than IgE to other moieties. As examples, gliadin-omega-5 is likely to be associated with more severe wheat allergy, and specific IgE antibodies to latex Hev b and Hev b 6.01 are strongly associated with positive specific inhalation challenge [<a href="#rid40">40,41</a>]. (See  <a class="medical medical_review" href="/d/html/95310.html" rel="external">"Grain allergy: Clinical features, diagnosis, and management", section on 'IgE-mediated presentations'</a>.)</p><p></p><p class="headingAnchor" id="H2882963338"><span class="h2">Pulmonary function tests</span><span class="headingEndMark"> — </span>Baseline spirometry before and after bronchodilator should be obtained in virtually all patients with suspected OA. If airflow limitation is not present, the next step is either nonspecific bronchoprovocation testing or serial peak flow or spirometry at work and at home. For patients who are no longer working, nonspecific bronchoprovocation is used to document the presence or absence of airway hyperresponsiveness.</p><p class="headingAnchor" id="H978191388"><span class="h3">Spirometry before and after bronchodilator</span><span class="headingEndMark"> — </span>Baseline spirometry before and after bronchodilator is used to determine the presence and severity of any airflow limitation [<a href="#rid44">44</a>]. The results of spirometry determine the most appropriate next test and are useful as a baseline for future assessments.</p><p>In a subject with airflow obstruction (ie, a ratio of forced expiratory volume in one second [FEV<sub>1</sub>]/forced vital capacity [FVC] below the lower limit of normal), the next step is to assess reversibility with inhaled bronchodilator. The presence of a significant increase in FEV<sub>1</sub> (10 percent of predicted value) after inhaling a bronchodilator supports the diagnosis of asthma. (See  <a class="medical medical_review" href="/d/html/569.html" rel="external">"Pulmonary function testing in asthma", section on 'Bronchodilator responses'</a>.)</p><p>Restrictive physiology in the absence of airflow limitation suggests that the patient’s symptoms may have an alternate etiology. Further evaluation usually includes full pulmonary function testing and radiographic imaging. (See  <a class="medical medical_review" href="/d/html/6969.html" rel="external">"Overview of pulmonary function testing in adults", section on 'Restrictive ventilatory defect'</a>.)</p><p class="headingAnchor" id="H3932520489"><span class="h3">Nonspecific bronchoprovocation challenge</span><span class="headingEndMark"> — </span>In the absence of airflow limitation at baseline, the next step is to assess nonspecific airway (bronchial) responsiveness, a characteristic feature of asthma [<a href="#rid45">45</a>]. Typically, a pharmacologic agent, such as <a class="drug drug_general" data-topicid="9622" href="/d/drug information/9622.html" rel="external">methacholine</a> or histamine, is used. (See  <a class="medical medical_review" href="/d/html/525.html" rel="external">"Bronchoprovocation testing"</a>.)</p><p>If the FEV<sub>1</sub> does not decrease by 20 percent with a <a class="drug drug_general" data-topicid="9622" href="/d/drug information/9622.html" rel="external">methacholine</a> dose of 16 mg/mL or less, the test excludes significant airway hyperresponsiveness [<a href="#rid46">46</a>]. Absence of airway hyperresponsiveness could be due to lack of recent exposure to the sensitizing agent in a worker who has been away from work, but virtually rules out occupational asthma in a worker who has continued to work and is symptomatic. For patients who have been away from the workplace and have negative initial bronchoprovocation testing, repeat bronchoprovocation testing after an exposure to the causative agent (in the laboratory or at work) may then reveal airway hyperresponsiveness. (See <a class="local">'Advanced testing'</a> below.)</p><p class="headingAnchor" id="H1771421556"><span class="h3">Serial peak expiratory flow measurement</span><span class="headingEndMark"> — </span>Serial measurement of peak expiratory flow (PEF) can be useful in the investigation and assessment of OA by demonstrating work-associated airflow limitation (eg, a decrease in peak flow by ≥20 percent at work compared with values at home) [<a href="#rid47">47-49</a>]. Serial PEF is sometimes used to confirm a diagnosis of asthma by demonstrating variable airflow limitation, but spirometry pre and post bronchodilator is preferred. (See <a class="local">'Spirometry before and after bronchodilator'</a> above.)</p><p>The subject is instructed on the proper use of the peak flow meter and asked to monitor his or her PEF a minimum of four times per day for a period of at least two weeks at work and during a similar period away from work (for a total monitoring time of at least three weeks) [<a href="#rid20">20,50</a>]. The period of testing at work should be shortened if the patient develops pronounced airway obstruction or has severe symptoms. The normal degree of PEF variation is &lt;15 percent, whereas variability ≥20 percent associated with workplace exposure supports OA. Diagnostically, multiple methods may be used to compare peak flow changes between days on and off work; some centers use a computerized quantitative approach [<a href="#rid22">22</a>]. (See  <a class="medical medical_review" href="/d/html/568.html" rel="external">"Peak expiratory flow monitoring in asthma"</a>.)</p><p>A number of potential problems are inherent to serial PEF monitoring, including the variable reproducibility of readings, compliance and honesty of subjects, interpretation of results, and sensitivity and specificity compared with specific inhalation challenges [<a href="#rid20">20</a>]. Newer portable peak flow meters store values electronically or online, enabling identification of falsified patient logs, although variable patient effort remains a problem. Interpretation of graphs of serial PEF measurements can be carried out by using a computer program called <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.occupationalasthma.com%2F&amp;token=mS0j6fatbhR4mA%2FurjnZxX%2BCQeZ2PgridQRvLSlJnfiJEKs%2FytnsUPgumVKYQc76&amp;TOPIC_ID=550" target="_blank">OASYS</a>, although other diagnostic approaches may be used [<a href="#rid51">51,52</a>]. Ideally, monitoring of PEF should be combined with monitoring of nonspecific bronchial (airway) responsiveness (NSBR) at and off work (see below). When there is discrepancy between changes in PEF and NSBR, further testing such as specific inhalation challenges may be required.</p><p class="headingAnchor" id="H803353830"><span class="h3">Serial spirometry at work</span><span class="headingEndMark"> — </span>Spirometry provides more detailed information about airflow and more reliable results than PEF monitoring [<a href="#rid53">53</a>], but serial spirometry has limited utility in evaluating OA. The spirometric parameter that is most reliable is the FEV<sub>1</sub>; changes in the FVC and forced expiratory flow at 25 to 75 percent of vital capacity are less reliable. A decrease in workplace FEV<sub>1</sub> ≥15 percent compared with home FEV<sub>1</sub> is considered positive. (See  <a class="medical medical_review" href="/d/html/6968.html" rel="external">"Office spirometry", section on 'Interpretation'</a>.)</p><p>Serial spirometry can be used to identify changes in airflow limitation in and away from the workplace, similar to the procedure for serial PEF monitoring [<a href="#rid53">53</a>]. However, unsupervised serial FEV<sub>1</sub> monitoring at and off work has not proven to be as reliable as serial PEF measurement [<a href="#rid54">54</a>]. Furthermore, portable spirometers are more expensive than PEF meters and the technical training more complex for the worker.</p><p>Comparisons between data from exposure and nonexposure days can support (or refute) work-related exacerbations of asthma. However, a single measurement of FEV<sub>1</sub> when the subject is at work and repeating once away from work (eg, pre and post shift) does not have sufficient sensitivity nor specificity to detect a relationship between work and asthma [<a href="#rid55">55-57</a>].</p><p>Periodic spirometry measurements can be used for workplace surveillance when occupational exposures place workers at risk for OA [<a href="#rid44">44,53</a>]. Typically, measurements are repeated at one to two year intervals, although periodic spirometry alone is not considered a sensitive tool for identifying new cases [<a href="#rid58">58</a>].</p><p class="headingAnchor" id="H4148676977"><span class="h2">Advanced testing</span><span class="headingEndMark"> — </span>For patients with a positive exposure history to a known inducer of OA, but nondiagnostic results from the above evaluation, additional tests (largely performed in specialized centers) may be useful  (<a class="graphic graphic_algorithm graphicRef138428" href="/d/graphic/138428.html" rel="external">algorithm 1</a> and <a class="graphic graphic_algorithm graphicRef138427" href="/d/graphic/138427.html" rel="external">algorithm 2</a>). Sputum eosinophil counts are time-consuming and require experienced laboratory personnel.</p><p class="headingAnchor" id="H3877797165"><span class="h3">Airway inflammation</span><span class="headingEndMark"> — </span>Identifying increased airway inflammation with noninvasive tests, such as sputum eosinophil counts and fractional concentration of exhaled nitric oxide (FE<sub>NO</sub>), at the end of a period at work or following laboratory challenge can provide supportive evidence of airway inflammation and, thus, indirect evidence of OA [<a href="#rid59">59</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sputum cell counts</strong> – Asthmatic airway inflammation may be characterized by the presence of eosinophils in induced sputum samples, especially in HMW induced OA; neutrophils may also be involved, especially in more severe asthma. Either eosinophilic or neutrophilic inflammation can be predominant, the latter being more common in OA induced by LMW agents  (<a class="graphic graphic_table graphicRef66185" href="/d/graphic/66185.html" rel="external">table 2</a>) [<a href="#rid60">60-62</a>].</p><p></p><p class="bulletIndent1">For patients who do not spontaneously raise sputum, inhalation of hypertonic <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> can be used to induce sputum, ideally 7 to 24 hours after exposure [<a href="#rid63">63,64</a>]. Typically, a sample of induced sputum is obtained at the end of the work day, after two weeks of work, and compared with a sample from the same time after a day at home, after two weeks off work. Inhalation of <a class="drug drug_general" data-topicid="9396" href="/d/drug information/9396.html" rel="external">albuterol</a> prior to sputum induction will inhibit airway obstruction induced by the hypertonic saline. One common method is to provide seven minutes of nebulization of increasing doses of saline solution (eg, 3, 4, and 5 percent) until sputum can be obtained. We use the Diff-Quik stain which is based upon a modification of the Wright Giemsa stain, although the Wright and Hansel stains are alternatives. The nonsquamous cell differential counts are expressed as a percentage of the total nonsquamous cell counts. This test is only available at specialized centers.</p><p></p><p class="bulletIndent1">The presence of eosinophils in induced sputum (≥2 percent) suggests that either asthma or eosinophilic bronchitis is present. Eosinophilic bronchitis can be occupationally induced and cause cough and sputum production in the absence of airway hyperresponsiveness [<a href="#rid65">65-67</a>]. (See <a class="local">'Nonspecific bronchoprovocation challenge'</a> above and  <a class="medical medical_review" href="/d/html/1428.html" rel="external">"Evaluation and treatment of subacute and chronic cough in adults", section on 'Nonasthmatic eosinophilic bronchitis'</a> and  <a class="medical medical_review" href="/d/html/1460.html" rel="external">"Causes and epidemiology of subacute and chronic cough in adults", section on 'Nonasthmatic eosinophilic bronchitis'</a>.)</p><p></p><p class="bulletIndent1">The use of sputum eosinophil counts in the diagnosis of OA was compared with PEF monitoring in a case series of 49 patients with suspected OA who were evaluated during two weeks at work and two weeks away [<a href="#rid59">59</a>]. The combination of work-related decreases in PEF and a greater than 1 percent increase in sputum eosinophils after two weeks at work increased both the sensitivity and specificity of OA diagnosis, compared with PEF monitoring alone. In a separate study, a 3 percent increase in sputum eosinophils following specific inhalation challenge had a positive predictive value of 75 percent for specific bronchial reactivity to occupational agents [<a href="#rid68">68</a>].</p><p></p><p class="bulletIndent1">In the presence of normal airway caliber and responsiveness and no change in PEF at work, a normal induced sputum cell content in a symptomatic patient with current workplace exposure to a known OA sensitizer excludes OA and further specific testing is not needed.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Exhaled nitric oxide</strong> – The FE<sub>NO</sub> generally correlates with sputum eosinophilia, but studies examining a role in the diagnosis of OA are conflicting [<a href="#rid69">69-73</a>], and the value of FE<sub>NO</sub> in the investigation of OA remains to be established [<a href="#rid70">70,74</a>]. (See  <a class="medical medical_review" href="/d/html/542.html" rel="external">"Exhaled nitric oxide analysis and applications"</a>.)</p><p></p><p class="bulletIndent1">The measurement of FE<sub>NO</sub> is appealing because it provides immediate results. However, it is sensitive to confounding factors, such as smoking, atopy, and treatment with inhaled glucocorticoids. The increase in FE<sub>NO</sub> is not uniform among subjects who experience a positive asthmatic reaction during specific inhalation challenge [<a href="#rid69">69,75</a>]. Among patients with a positive specific inhalation challenge to an occupational agent, a greater increase in FE<sub>NO</sub> is observed among those with sensitivity to a HMW agent than a LMW agent [<a href="#rid76">76</a>]. The use of FE<sub>NO</sub> may be more useful in patients exposed to HMW agents, where an IgE-dependent reaction is involved, than in patients exposed to LMW agents [<a href="#rid76">76</a>].</p><p></p><p class="bulletIndent1">While a positive SIC is often associated with increased FE<sub>NO</sub>, FE<sub>NO</sub> cannot invalidate or confirm a diagnosis of OA [<a href="#rid77">77</a>].</p><p></p><p class="headingAnchor" id="H1441179838"><span class="h3">Variation in nonspecific bronchial responsiveness</span><span class="headingEndMark"> — </span>Increased nonspecific bronchial (airway) responsiveness (NSBR) can last for years in patients with established OA; in milder OA, it resolves much more quickly, but will last for at least a day or two. Thus, NSBR can be measured after two or more weeks away from work and again after workplace exposure to obtain more objective evidence of an occupational cause of symptoms and airflow limitation [<a href="#rid20">20</a>]. This testing is particularly helpful when the baseline spirometry and initial testing of NSBR are normal.</p><p>Airway hyperresponsiveness is usually assessed with direct challenges using <a class="drug drug_general" data-topicid="9622" href="/d/drug information/9622.html" rel="external">methacholine</a> or histamine, but indirect challenges using <a class="drug drug_general" data-topicid="9587" href="/d/drug information/9587.html" rel="external">mannitol</a> may also be helpful in assessing patients with occupational asthma, especially to appreciate the severity of their disease [<a href="#rid78">78</a>]. (See  <a class="medical medical_review" href="/d/html/525.html" rel="external">"Bronchoprovocation testing", section on 'Pharmacologic challenge'</a>.)</p><p>When assessing changes in bronchoprovocation before and after workplace or laboratory exposure, a change of 3.2-fold (eg, 16 mg/mL to 4 mg/mL) in the concentration of <a class="drug drug_general" data-topicid="9622" href="/d/drug information/9622.html" rel="external">methacholine</a> or histamine that causes a 20 percent fall in FEV<sub>1</sub> is considered clinically significant [<a href="#rid79">79</a>].</p><p>When a symptomatic subject is tested within 24 hours of exposure to the suspected work sensitizer, the absence of increased NSBR virtually excludes OA [<a href="#rid80">80</a>]. As an exception, normal responsiveness has been shown in a very few instances, generally in workers who experience an isolated immediate reaction, without delayed bronchoconstriction several hours later. On the other hand, absence from work for several days or longer has been associated with a falsely negative <a class="drug drug_general" data-topicid="9622" href="/d/drug information/9622.html" rel="external">methacholine</a> inhalation challenge [<a href="#rid81">81,82</a>]. If bronchoprovocation testing is negative, but OA is still strongly suspected clinically, skin or immunoassay testing may provide evidence of sensitization. For confirmation of OA in this setting, specific inhalation challenge with the relevant agent is needed. (See <a class="local">'Specific inhalation challenge'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nonasthmatic eosinophilic bronchitis</strong> – When nonspecific bronchoprovocation challenge testing is negative despite ongoing exposure, induced sputum may be assessed to identify occupational nonasthmatic eosinophilic bronchitis as a cause of the patient’s symptoms [<a href="#rid65">65</a>]. (See <a class="local">'Airway inflammation'</a> above and  <a class="medical medical_review" href="/d/html/1428.html" rel="external">"Evaluation and treatment of subacute and chronic cough in adults", section on 'Nonasthmatic eosinophilic bronchitis'</a> and  <a class="medical medical_review" href="/d/html/1460.html" rel="external">"Causes and epidemiology of subacute and chronic cough in adults", section on 'Nonasthmatic eosinophilic bronchitis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Surveillance</strong> – Surveillance of asymptomatic workers is generally performed by the workplace. Nonspecific bronchoprovocation challenge is one of the potential tools used to assess development of sensitization. In asymptomatic workers who are undergoing surveillance because of known exposure to an occupational sensitizer, an increase in NSBR and sputum eosinophil numbers after antigen exposure may precede the onset of asthmatic reactions and provide an early and sensitive marker of an abnormal airway response to inhalation of occupational agents [<a href="#rid83">83,84</a>]. (See <a class="local">'Airway inflammation'</a> above.)</p><p></p><p class="headingAnchor" id="H2834480084"><span class="h3">Specific inhalation challenge</span><span class="headingEndMark"> — </span>Specific inhalation challenge (SIC; also called specific bronchoprovocation challenge) with specific occupational agents is performed in specialized centers [<a href="#rid85">85</a>]. The number of available centers is small [<a href="#rid86">86,87</a>]. Specific bronchoprovocation challenge involves exposing subjects to occupational agents in a hospital laboratory or, occasionally, at work [<a href="#rid88">88</a>]. When these tests are carried out in a hospital laboratory, low doses of the occupational agent are used to avoid a nonspecific irritant effect. Dose response curves are constructed in which the dose (concentration multiplied by duration) is progressively increased and compared with lung function changes. A control test without exposure (or with exposure to a control substance mimicking the suspected agent) is always performed on a separate day [<a href="#rid89">89,90</a>]. (See  <a class="medical medical_review" href="/d/html/525.html" rel="external">"Bronchoprovocation testing", section on 'Antigen challenge'</a>.)</p><p>In general, specific bronchoprovocation challenges are carried out if other tests are inconclusive, rather than being used for routine diagnosis [<a href="#rid86">86,91</a>]. For example, they can be performed in patients with documented airway hyperresponsiveness when skin or immunoassay testing is not available and results of serial peak expiratory flow or spirometry measurements are unclear about whether asthma is occupationally induced.</p><p>In the case of high molecular weight agents, specific bronchoprovocation testing can be carried out in a single day, because an immediate reaction that is maximal during the first hour following exposure is expected. LMW agents often cause nonimmediate or late reactions and therefore require daily challenges of escalating doses of the agent on sequential days.</p><p>If airflow obstruction is not induced by inhalation of the specific agent, assessment of NSBR is carried out toward the end of the challenge day or at 24 hours after inhalation. An increase in NSBR, sputum eosinophils, or exhaled nitric oxide after specific antigen challenge supports the likelihood that the patient has OA or nonasthmatic eosinophilic bronchitis due to that agent. A negative specific bronchoprovocation challenge in the laboratory may not exclude entirely the diagnosis of OA as the worker may have become “desensitized” or the wrong agent may have been used [<a href="#rid91">91</a>]. If possible, the worker should return to work and be reassessed if symptoms develop [<a href="#rid88">88</a>].</p><p>Specific inhalation challenges appear safe especially when the exposure to LMW agents is spread over a few days with a short exposure on the first day (eg, one to four minutes), as recommended [<a href="#rid92">92</a>]. When the challenge to LMW agents was performed on a single day only, 3 percent of the patients tested experienced a severe asthmatic reaction requiring repeated administration of a short acting beta-2 agonist and oral or systemic glucocorticoids [<a href="#rid93">93</a>].</p><p class="headingAnchor" id="H502867492"><span class="h2">Imaging</span><span class="headingEndMark"> — </span>A chest radiograph is often obtained in adults who present with new onset or work-related dyspnea to exclude causes of dyspnea and cough other than OA. The chest radiograph in OA may be normal or may show hyperinflation. High-resolution computed tomography (HRCT) is usually not needed for the evaluation of a patient with suspected OA, unless an unexplained abnormality is noted on the plain chest radiograph.</p><p>A possible exception is when a worker has known exposure to agents that cause both OA and hypersensitivity pneumonitis (eg, acid anhydrides, isocyanates). In that setting and when there is suspicion of hypersensitivity pneumonitis, an HRCT scan, combined with pulmonary function testing, may help in differentiating between these possibilities. (See <a class="local">'Confirmation of asthma'</a> below and  <a class="medical medical_review" href="/d/html/4313.html" rel="external">"Hypersensitivity pneumonitis (extrinsic allergic alveolitis): Clinical manifestations and diagnosis", section on 'High resolution computed tomography'</a> and  <a class="medical medical_review" href="/d/html/14874.html" rel="external">"Imaging of occupational lung diseases"</a>.)</p><p class="headingAnchor" id="H344158038"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of OA is based upon the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Evidence of reversible airflow limitation (ie, asthma)</p><p class="bulletIndent1"><span class="glyph">●</span>A combination of exposure to a sensitizing agent at work  (<a class="graphic graphic_table graphicRef66185" href="/d/graphic/66185.html" rel="external">table 2</a>) and the presence of latency, (ie, the time course of symptom onset relative to start of a particular workplace exposure)</p><p class="bulletIndent1"><span class="glyph">●</span>Specific testing that establishes an occupational contribution  (<a class="graphic graphic_algorithm graphicRef138428" href="/d/graphic/138428.html" rel="external">algorithm 1</a> and <a class="graphic graphic_algorithm graphicRef138427" href="/d/graphic/138427.html" rel="external">algorithm 2</a>).</p><p></p><p class="headingAnchor" id="H6"><span class="h2">Confirmation of asthma</span><span class="headingEndMark"> — </span>The first step in evaluating a patient with suspected OA is to confirm that the patient indeed has asthma. The diagnosis of asthma based on history alone may not be accurate, and therefore pulmonary function testing is warranted, starting with assessment of spirometry pre and post bronchodilator. (See <a class="local">'Pulmonary function tests'</a> above and  <a class="medical medical_review" href="/d/html/569.html" rel="external">"Pulmonary function testing in asthma"</a> and  <a class="medical medical_review" href="/d/html/543.html" rel="external">"Asthma in adolescents and adults: Evaluation and diagnosis"</a>.)</p><p>Asthma is confirmed in one of the following ways:</p><p class="bulletIndent1"><span class="glyph">●</span>Reversible airflow limitation demonstrated with spirometry pre and post bronchodilator. (See <a class="local">'Spirometry before and after bronchodilator'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with normal baseline spirometry, positive nonspecific bronchoprovocation challenge confirms asthma. If the testing is negative in a symptomatic patient who has ongoing exposure in the workplace, OA is unlikely. However, if bronchoprovocation challenge is negative in a patient who is not working, it remains possible that nonspecific airway (bronchial) hyperresponsiveness has waned in the absence of exposure. If the patient is able to return to work, bronchoprovocation challenge should be repeated. (See <a class="local">'Nonspecific bronchoprovocation challenge'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Demonstration of variable airflow limitation by serial measurement of peak expiratory flow (PEF) or spirometry in and away from the workplace can be helpful but is less reliable for a firm diagnosis of asthma. (See <a class="local">'Serial peak expiratory flow measurement'</a> above and <a class="local">'Serial spirometry at work'</a> above.)</p><p></p><p class="headingAnchor" id="H7"><span class="h2">Establishing occupational relationship</span><span class="headingEndMark"> — </span>For those patients who have a clear diagnosis of asthma, the next step is to establish that an occupational agent is causing the worker’s asthma and, when possible, to identify the causative agent. Given the important implications of establishing the diagnosis for both health and employment, it is best to establish the workplace association prior to initiation of maintenance treatment or workplace adaptations [<a href="#rid22">22</a>]. Several tests are available to determine whether a given patient's symptoms are due to OA and whether a particular occupational exposure is the inciting agent [<a href="#rid20">20</a>]. Stepwise schemes have been proposed for the diagnosis of OA using these various methods [<a href="#rid94">94</a>]. The exact order and combination of testing depends on whether the patient still has workplace exposure or not and the availability of testing  (<a class="graphic graphic_algorithm graphicRef138428" href="/d/graphic/138428.html" rel="external">algorithm 1</a> and <a class="graphic graphic_algorithm graphicRef138427" href="/d/graphic/138427.html" rel="external">algorithm 2</a>).</p><p class="headingAnchor" id="H3795392170"><span class="h3">Patients who are working</span><span class="headingEndMark"> — </span>For patients who continue to work or can return to the workplace, serial testing of PEF during and away from workplace exposures is a standard and widely available method for identifying OA. Skin testing and immunoassays to agents known to cause OA have limited availability, but should be performed if available. When positive in a patient with known exposure to that agent and objective evidence of asthma, the likelihood of OA is high. However, a positive allergy test is not diagnostic of OA, and a negative reaction does not exclude OA. Combining nonspecific bronchial responsiveness (NSBR) monitoring with serial PEF monitoring at and away from work improves the accuracy of the diagnosis.</p><p>Where available, combining monitoring of NSBR and induced sputum analysis with PEF measured at and away from work can further increase the accuracy of testing. (See <a class="local">'Serial peak expiratory flow measurement'</a> above and <a class="local">'Serial spirometry at work'</a> above and <a class="local">'Airway inflammation'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Confident diagnosis of OA</strong> – Decreases in PEF noted at work <strong>and</strong> significant reduction in NSBR away from work. An increase in eosinophils (&gt;1 to 2 percent) at the end of the workday relative to a sample from the same time of day at home helps support the diagnosis. Absence of change in sputum eosinophils does not negate the diagnosis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>OA likely, but not definite</strong> – Work-related decreases in PEF without a work-related change in NSBR or increase in sputum eosinophils. If a definite diagnosis of OA is necessary in such a patient, referral to a center that could perform specific inhalation challenge to the presumed culprit agent would be required. Of note, a positive SIC is required for a diagnosis of OA in Canada, but not in the United States. (See <a class="local">'Specific inhalation challenge'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>OA unlikely</strong> – Absence of a work-related decrease in PEF, absence of NSBR changes at and off work, and absence of an increase in sputum eosinophils. If strong clinical suspicion for OA remains, referral to a center that offers specific bronchoprovocation challenge can provide a definitive result. (See <a class="local">'Specific inhalation challenge'</a> above.)</p><p></p><p class="headingAnchor" id="H2800405075"><span class="h3">Patients who are not working</span><span class="headingEndMark"> — </span>A definitive diagnosis of OA can be more difficult to make in patients who no longer have workplace exposure, because nonspecific bronchial hyperresponsiveness (NSBH) tends to wane the longer the person is away from the workplace and serial lung function monitoring cannot be performed. The initial steps are to assess skin testing or immunoassays for evidence of sensitization to potential causes of OA (where available) and confirm objective evidence of asthma based on spirometry pre and post bronchodilator or nonspecific bronchoprovocation challenge.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Likely diagnosis of OA</strong> – Positive skin test or immunoassay <strong>and</strong> objective evidence of asthma. Resolution of asthma symptoms away from the workplace lends further support to the diagnosis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sensitization without current evidence of OA</strong> – Positive skin test or immunoassay, but normal spirometry and a negative bronchoprovocation challenge. As the person is no longer working, NSBH may have resolved. Specific inhalation challenge, possibly followed by repeat nonspecific bronchoprovocation challenge, may help establish the diagnosis. (See <a class="local">'Advanced testing'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Confirmation of asthma, but diagnosis of OA unclear</strong> – Negative skin test or immunoassay, but objective confirmation of asthma. Definitive diagnosis of OA would require a positive specific bronchoprovocation challenge. In the absence of specific inhalation challenge, a likely diagnosis of OA would depend on whether the history of asthma onset, exposure to a causative agent, and improvement away from the workplace strongly suggest OA. (See <a class="local">'Advanced testing'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>OA unlikely</strong> – Skin test or immunoassay <strong>and</strong> nonspecific bronchoprovocation challenge are negative. Any current symptoms would be unlikely due to OA. A small possibility remains that the patient’s workplace symptoms were due to OA, but the NSBH resolved after the person left the workplace (if several weeks have elapsed). The only way to make a definitive diagnosis would be via specific bronchoprovocation challenge, possibly followed by repeat nonspecific bronchoprovocation challenge. (See <a class="local">'Advanced testing'</a> above.)</p><p></p><p class="headingAnchor" id="H1807659933"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>A number of disease processes have symptoms that mimic OA, such as asthma due to nonoccupational causes, chronic obstructive pulmonary disease (COPD), nonasthmatic eosinophilic bronchitis, work-related irritable larynx syndrome, upper respiratory tract irritation, hyperventilation syndrome, occupational rhinitis, hypersensitivity pneumonitis, and bronchiolitis obliterans. Certain distinguishing features can help to differentiate OA from the other diagnoses. The evaluation and diagnosis of asthma and occupational rhinitis are discussed separately. (See  <a class="medical medical_review" href="/d/html/543.html" rel="external">"Asthma in adolescents and adults: Evaluation and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/7529.html" rel="external">"Occupational rhinitis"</a> and  <a class="medical medical_review" href="/d/html/543.html" rel="external">"Asthma in adolescents and adults: Evaluation and diagnosis", section on 'Differential diagnosis'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>COPD</strong> – Workers can develop COPD due to personal or workplace exposure to tobacco smoke, irritants such as coal mine dust, and other pollutants. A careful history can elicit the intensity and duration of these exposures. Spirometry will typically show a substantial component of irreversible airflow obstruction in patients with COPD. (See  <a class="medical medical_review" href="/d/html/1455.html" rel="external">"Chronic obstructive pulmonary disease: Diagnosis and staging", section on 'Spirometry'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Occupational Asthma and COPD Overlap (OACO)</strong> – Asthma and COPD may exist concurrently in some workers, and the syndrome presents with airflow obstruction not fully reversible with bronchodilator treatment. In a comparison of workers with OACO versus OA, those with OACO tended to be older, were exposed to the triggering agent for a longer period of time, were more frequently exposed to LMW agents, were treated with higher doses of inhaled glucocorticoids, and were less atopic [<a href="#rid95">95,96</a>]. (See  <a class="medical medical_review" href="/d/html/122856.html" rel="external">"Asthma and COPD overlap (ACO)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nonasthmatic eosinophilic bronchitis (NAEB)</strong> – NAEB due to occupational exposure differs from OA by the absence of airway hyperresponsiveness and airflow obstruction. Sputum cell count analysis shows a significant increase in the percentage of eosinophils when the patient is exposed to the occupational agent to which they are sensitized, with a significant decrease after removal from exposure. (See  <a class="medical medical_review" href="/d/html/1428.html" rel="external">"Evaluation and treatment of subacute and chronic cough in adults", section on 'Nonasthmatic eosinophilic bronchitis'</a> and  <a class="medical medical_review" href="/d/html/1460.html" rel="external">"Causes and epidemiology of subacute and chronic cough in adults", section on 'Nonasthmatic eosinophilic bronchitis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Work-related irritable larynx syndrome</strong> – Work-related irritable larynx syndrome refers to hyperkinetic laryngeal symptoms triggered by sensory stimuli in the workplace, such as odors and irritants [<a href="#rid97">97</a>]. This syndrome includes inducible laryngeal obstruction (ILO; also known as paradoxical vocal fold motion or vocal cord dysfunction), dysphonia due to laryngeal muscle tension (also known as muscle tension dysphonia), globus (ie, sensation of tension in the throat or neck), and chronic cough. In a case series of workers with work-related irritable larynx, dysphonia was present in 86 percent and chronic cough in 76 percent [<a href="#rid97">97</a>].</p><p></p><p class="bulletIndent1">ILO can mimic asthma and OA, and can also coexist with these diagnoses [<a href="#rid98">98</a>]. Typically, the diagnosis of ILO is suspected when the patient has noisy, high-pitched breathing sounds (stridor), loudest above the throat and less audible through the chest wall, dysphonia, and an abnormal inspiratory flow volume curve, and does not respond as expected to treatment with an inhaled bronchodilator. Ascertaining the diagnosis requires the visualization of paradoxical motion of the vocal folds or supraglottic narrowing during symptoms. (See  <a class="medical medical_review" href="/d/html/523.html" rel="external">"Inducible laryngeal obstruction (paradoxical vocal fold motion)"</a> and  <a class="medical medical_review" href="/d/html/1465.html" rel="external">"Flow-volume loops", section on 'Variable extrathoracic obstruction'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hyperventilation syndrome</strong> – Hyperventilation syndrome is frequently misdiagnosed as asthma [<a href="#rid25">25,99</a>]. It is characterized by a variety of somatic symptoms induced by physiologically inappropriate hyperventilation and usually reproduced in whole or in part by voluntary hyperventilation. (See  <a class="medical medical_review" href="/d/html/16288.html" rel="external">"Hyperventilation syndrome in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypersensitivity pneumonitis</strong> – A number of the same antigens that cause OA can also cause hypersensitivity pneumonitis. Unlike OA, hypersensitivity pneumonitis is typically associated with a restrictive ventilatory defect and interstitial opacities on radiographic imaging. (See  <a class="medical medical_review" href="/d/html/4309.html" rel="external">"Hypersensitivity pneumonitis (extrinsic allergic alveolitis): Epidemiology, causes, and pathogenesis", section on 'Etiologic agents'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bronchiolitis obliterans</strong> – Bronchiolitis obliterans presents with dyspnea and cough; airflow limitation on spirometry, when present, is typically not reversible. Silo filler’s disease due to inhalation of high concentrations of nitrogen dioxide is a classic example of bronchiolitis obliterans. Bronchiolitis obliterans has also been reported in popcorn workers and as a rare manifestation in nylon flock workers [<a href="#rid100">100,101</a>]. (See  <a class="medical medical_review" href="/d/html/4323.html" rel="external">"Overview of bronchiolar disorders in adults", section on 'Cessation of culprit drugs and exposures'</a> and  <a class="medical medical_review" href="/d/html/4314.html" rel="external">"Flock worker's lung"</a>.)</p><p></p><p class="headingAnchor" id="H3447172808"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/112673.html" rel="external">"Society guideline links: Occupational asthma"</a>.)</p><p class="headingAnchor" id="H14"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> – Occupational asthma (OA) is characterized by variable airflow obstruction, airway hyperresponsiveness, and airway inflammation attributable to a particular occupational exposure and not due to stimuli encountered outside the workplace. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – The typical symptoms of OA are the same as nonoccupational asthma and include cough, sputum production, dyspnea, wheeze, and chest tightness. Some patients report a pattern of increased symptoms while at work or within several hours of the completion of a shift and improvement on weekends or during vacations. Patients may also have symptoms of work-related rhinoconjunctivitis that precede or accompany the onset of OA. (See <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation</strong> – A stepwise testing approach based on whether or not the patient continues to work can be useful to reach a diagnosis of OA  (<a class="graphic graphic_algorithm graphicRef138428" href="/d/graphic/138428.html" rel="external">algorithm 1</a> and <a class="graphic graphic_algorithm graphicRef138427" href="/d/graphic/138427.html" rel="external">algorithm 2</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Occupational history</strong> – Although insufficient on its own to confirm or exclude the diagnosis, a work history is an essential component of the evaluation of OA. It should generally include current and previous job titles, job descriptions, known exposures, and also any exposures to unidentified vapors, gas, fumes, or dust  (<a class="graphic graphic_table graphicRef66185" href="/d/graphic/66185.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef122138" href="/d/graphic/122138.html" rel="external">table 1</a>). (See <a class="local">'Occupational history'</a> above.)</p><p></p><p class="bulletIndent2">In general, the latency period from initial exposure to onset of symptoms (sensitization) is shorter with low molecular weight (LMW) agents than with high molecular weight (HMW) agents  (<a class="graphic graphic_table graphicRef66185" href="/d/graphic/66185.html" rel="external">table 2</a>). However, onset of symptoms on a given day typically occurs faster with HMW agents than LMW agents. (See <a class="local">'Occupational history'</a> above.)</p><p></p><p class="bulletIndent2">For HMW agents, work-related wheezing and nasal symptoms suggest OA. For LMW agents, no specific symptom question accurately predicts OA. (See <a class="local">'Occupational history'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Skin and immunologic testing</strong> – When available, skin test reactivity or immunoassay for specific immunoglobulin E (IgE) can identify sensitization to known occupational sensitizers. (See <a class="local">'Establishing occupational relationship'</a> above and <a class="local">'Skin and immunologic testing'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Confirmation of asthma</strong> – The evaluation of suspected OA generally requires tests to confirm asthma and determine whether a particular occupational exposure is the inciting agent. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Initial testing includes spirometry before and after bronchodilator to determine the presence, severity, and reversibility of any airflow limitation. (See <a class="local">'Spirometry before and after bronchodilator'</a> above and <a class="local">'Confirmation of asthma'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>In the absence of airflow limitation, a nonspecific bronchoprovocation challenge (eg, <a class="drug drug_general" data-topicid="9622" href="/d/drug information/9622.html" rel="external">methacholine</a>) is helpful to confirm or exclude current asthma. For patients who have ongoing work exposure and are symptomatic, a negative bronchoprovocation challenge makes OA unlikely. (See <a class="local">'Nonspecific bronchoprovocation challenge'</a> above and <a class="local">'Confirmation of asthma'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Establishing an occupational relationship</strong> – For patients who meet objective criteria for asthma and continue to work, monitoring of peak expiratory flow (PEF) or nonspecific bronchial responsiveness (if available) during and away from workplace exposures is useful to assess a workplace contribution. (See <a class="local">'Establishing occupational relationship'</a> above and <a class="local">'Serial peak expiratory flow measurement'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>In those with symptoms and ongoing workplace exposures, absence of nonspecific bronchial responsiveness, lack of sputum eosinophilia, and negative PEF monitoring in combination virtually excludes the possibility of OA. (See <a class="local">'Variation in nonspecific bronchial responsiveness'</a> above.)</p><p></p><p class="bulletIndent2">For patients with adult-onset asthma and suspected OA, but uncertainty about the provocative agent, specific bronchoprovocation testing at the workplace may be helpful. Such testing is only available in specialized centers. (See <a class="local">'Specific inhalation challenge'</a> above and  <a class="medical medical_review" href="/d/html/525.html" rel="external">"Bronchoprovocation testing", section on 'Antigen challenge'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Occupational nonasthmatic eosinophilic bronchitis (NAEB)</strong> – Occupational NAEB is an infrequent cause of occupational respiratory symptoms without bronchial hyperresponsiveness. (See <a class="local">'Airway inflammation'</a> above and <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Other allergic and pulmonary diseases</strong> – Other diseases that share features with OA include: asthma due to nonoccupational causes, chronic obstructive pulmonary disease (COPD), hyperventilation syndrome, upper respiratory tract irritation, occupational rhinitis, hypersensitivity pneumonitis, and bronchiolitis obliterans. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="headingAnchor" id="H6019454"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Moira Chan-Yeung, MD, Jean-Luc Malo, MD, André Cartier, MD, and Louis-Philippe Boulet, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Tarlo S, Vandenplas O, Bernstein DI, Malo JL. Definition and classification of asthma in the workplace. In: Asthma in the workplace, 5th, Tarlo S, Bernstein DI, Malo JL, Vandenplas O (Eds), CRC Press, Boca Raton, FL 2022. p.3.</li><li><a class="nounderline abstract_t">Quirce S, Sastre J. Occupational asthma: clinical phenotypes, biomarkers, and management. Curr Opin Pulm Med 2019; 25:59.</a></li><li><a class="nounderline abstract_t">Vandenplas O, Godet J, Hurdubaea L, et al. Are high- and low-molecular-weight sensitizing agents associated with different clinical phenotypes of occupational asthma? Allergy 2019; 74:261.</a></li><li><a class="nounderline abstract_t">Gautrin D, Ghezzo H, Infante-Rivard C, Malo JL. Natural history of sensitization, symptoms and occupational diseases in apprentices exposed to laboratory animals. Eur Respir J 2001; 17:904.</a></li><li><a class="nounderline abstract_t">Malo JL, Lemière C, Desjardins A, Cartier A. Prevalence and intensity of rhinoconjunctivitis in subjects with occupational asthma. Eur Respir J 1997; 10:1513.</a></li><li><a class="nounderline abstract_t">Siracusa A, Desrosiers M, Marabini A. Epidemiology of occupational rhinitis: prevalence, aetiology and determinants. Clin Exp Allergy 2000; 30:1519.</a></li><li><a class="nounderline abstract_t">Castano R, Gautrin D, Thériault G, et al. Occupational rhinitis in workers investigated for occupational asthma. Thorax 2009; 64:50.</a></li><li><a class="nounderline abstract_t">Vandenplas O, Ghezzo H, Munoz X, et al. What are the questionnaire items most useful in identifying subjects with occupational asthma? Eur Respir J 2005; 26:1056.</a></li><li><a class="nounderline abstract_t">Eifan AO, Derman O, Kanbur N, et al. Occupational asthma in apprentice adolescent car painters. Pediatr Allergy Immunol 2005; 16:662.</a></li><li><a class="nounderline abstract_t">Sastre J, Carnes J, García del Potro M, et al. Occupational asthma caused by triglycidyl isocyanurate. Int Arch Occup Environ Health 2011; 84:547.</a></li><li><a class="nounderline abstract_t">Redlich CA. Skin exposure and asthma: is there a connection? Proc Am Thorac Soc 2010; 7:134.</a></li><li><a class="nounderline abstract_t">Bello D, Herrick CA, Smith TJ, et al. Skin exposure to isocyanates: reasons for concern. Environ Health Perspect 2007; 115:328.</a></li><li><a class="nounderline abstract_t">Redlich CA, Herrick CA. Lung/skin connections in occupational lung disease. Curr Opin Allergy Clin Immunol 2008; 8:115.</a></li><li><a class="nounderline abstract_t">Kusaka Y. [Asthma due to hard alloy dusts--a case of allergic bronchial asthma and contact dermatitis due to metallic cobalt]. Nihon Kyobu Shikkan Gakkai Zasshi 1983; 21:582.</a></li><li><a class="nounderline abstract_t">Lynde CB, Obadia M, Liss GM, et al. Cutaneous and respiratory symptoms among professional cleaners. Occup Med (Lond) 2009; 59:249.</a></li><li><a class="nounderline abstract_t">Bousquet J, Flahault A, Vandenplas O, et al. Natural rubber latex allergy among health care workers: a systematic review of the evidence. J Allergy Clin Immunol 2006; 118:447.</a></li><li><a class="nounderline abstract_t">Arrandale VH, Liss GM, Tarlo SM, et al. Occupational contact allergens: are they also associated with occupational asthma? Am J Ind Med 2012; 55:353.</a></li><li><a class="nounderline abstract_t">Castano R, Trudeau C, Ghezzo H. Correlation between acoustic rhinometry and subjective nasal patency during nasal challenge test in subjects with suspected occupational rhinitis; a prospective controlled study. Clin Otolaryngol 2010; 35:462.</a></li><li><a class="nounderline abstract_t">Dykewicz MS. Occupational asthma: current concepts in pathogenesis, diagnosis, and management. J Allergy Clin Immunol 2009; 123:519.</a></li><li><a class="nounderline abstract_t">Tarlo SM, Balmes J, Balkissoon R, et al. Diagnosis and management of work-related asthma: American College Of Chest Physicians Consensus Statement. Chest 2008; 134:1S.</a></li><li><a class="nounderline abstract_t">Blanc PD, Annesi-Maesano I, Balmes JR, et al. The Occupational Burden of Nonmalignant Respiratory Diseases. An Official American Thoracic Society and European Respiratory Society Statement. Am J Respir Crit Care Med 2019; 199:1312.</a></li><li><a class="nounderline abstract_t">Barber CM, Cullinan P, Feary J, et al. British Thoracic Society Clinical Statement on occupational asthma. Thorax 2022; 77:433.</a></li><li><a class="nounderline abstract_t">Le Moual N, Bakke P, Orlowski E, et al. Performance of population specific job exposure matrices (JEMs): European collaborative analyses on occupational risk factors for chronic obstructive pulmonary disease with job exposure matrices (ECOJEM). Occup Environ Med 2000; 57:126.</a></li><li><a class="nounderline abstract_t">Cartier A. New causes of immunologic occupational asthma 2014-2020. Curr Opin Allergy Clin Immunol 2021; 21:110.</a></li><li><a class="nounderline abstract_t">Malo JL, Ghezzo H, L'Archevêque J, et al. Is the clinical history a satisfactory means of diagnosing occupational asthma? Am Rev Respir Dis 1991; 143:528.</a></li><li><a class="nounderline abstract_t">Baur X, Huber H, Degens PO, et al. Relation between occupational asthma case history, bronchial methacholine challenge, and specific challenge test in patients with suspected occupational asthma. Am J Ind Med 1998; 33:114.</a></li><li><a class="nounderline abstract_t">Vandenplas O, Binard-Van Cangh F, Brumagne A, et al. Occupational asthma in symptomatic workers exposed to natural rubber latex: evaluation of diagnostic procedures. J Allergy Clin Immunol 2001; 107:542.</a></li><li><a class="nounderline abstract_t">Quinlan PJ, Earnest G, Eisner MD, et al. Performance of self-reported occupational exposure compared to a job-exposure matrix approach in asthma and chronic rhinitis. Occup Environ Med 2009; 66:154.</a></li><li><a class="nounderline abstract_t">Siracusa A, Folletti I, Gerth van Wijk R, et al. Occupational anaphylaxis--an EAACI task force consensus statement. Allergy 2015; 70:141.</a></li><li><a class="nounderline abstract_t">Bernstein JA. Material safety data sheets: are they reliable in identifying human hazards? J Allergy Clin Immunol 2002; 110:35.</a></li><li class="breakAll">Henneberger PK, Wagner GR, Lau A, et al. Asthma exacerbated at work. In: Asthma in the workplace, 5th ed, Tarlo S, Bernstein DI, Malo JL, Vandenplas O (Eds), Taylor and Francis, Boca Raton 2022. p.251.</li><li><a class="nounderline abstract_t">Lemière C, Boulet LP, Chaboillez S, et al. Work-exacerbated asthma and occupational asthma: do they really differ? J Allergy Clin Immunol 2013; 131:704.</a></li><li><a class="nounderline abstract_t">Malo JL. Future advances in work-related asthma and the impact on occupational health. Occup Med (Lond) 2005; 55:606.</a></li><li><a class="nounderline abstract_t">Zock JP, Kogevinas M, Sunyer J, et al. Asthma characteristics in cleaning workers, workers in other risk jobs and office workers. Eur Respir J 2002; 20:679.</a></li><li><a class="nounderline abstract_t">Malo JL, Ghezzo H, D'Aquino C, et al. Natural history of occupational asthma: relevance of type of agent and other factors in the rate of development of symptoms in affected subjects. J Allergy Clin Immunol 1992; 90:937.</a></li><li><a class="nounderline abstract_t">Vandenplas O. Occupational asthma: etiologies and risk factors. Allergy Asthma Immunol Res 2011; 3:157.</a></li><li><a class="nounderline abstract_t">Slovak AJ, Hill RN. Does atopy have any predictive value for laboratory animal allergy? A comparison of different concepts of atopy. Br J Ind Med 1987; 44:129.</a></li><li><a class="nounderline abstract_t">van Kampen V, de Blay F, Folletti I, et al. EAACI position paper: skin prick testing in the diagnosis of occupational type I allergies. Allergy 2013; 68:580.</a></li><li><a class="nounderline abstract_t">Lux H, Lenz K, Budnik LT, Baur X. Performance of specific immunoglobulin E tests for diagnosing occupational asthma: a systematic review and meta-analysis. Occup Environ Med 2019; 76:269.</a></li><li><a class="nounderline abstract_t">Tarlo SM, Malo JL, de Blay F, et al. An Official American Thoracic Society Workshop Report: Presentations and Discussion of the Sixth Jack Pepys Workshop on Asthma in the Workplace. Ann Am Thorac Soc 2017; 14:1361.</a></li><li><a class="nounderline abstract_t">Vandenplas O, Froidure A, Meurer U, et al. The role of allergen components for the diagnosis of latex-induced occupational asthma. Allergy 2016; 71:840.</a></li><li><a class="nounderline abstract_t">Raulf M, Quirce S, Vandenplas O. Addressing Molecular Diagnosis of Occupational Allergies. Curr Allergy Asthma Rep 2018; 18:6.</a></li><li><a class="nounderline abstract_t">Dramburg S, Hilger C, Santos AF, et al. EAACI Molecular Allergology User's Guide 2.0. Pediatr Allergy Immunol 2023; 34 Suppl 28:e13854.</a></li><li><a class="nounderline abstract_t">Redlich CA, Tarlo SM, Hankinson JL, et al. Official American Thoracic Society technical standards: spirometry in the occupational setting. Am J Respir Crit Care Med 2014; 189:983.</a></li><li><a class="nounderline abstract_t">Nair P, Martin JG, Cockcroft DC, et al. Airway Hyperresponsiveness in Asthma: Measurement and Clinical Relevance. J Allergy Clin Immunol Pract 2017; 5:649.</a></li><li><a class="nounderline abstract_t">Crapo RO, Casaburi R, Coates AL, et al. Guidelines for methacholine and exercise challenge testing-1999. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. Am J Respir Crit Care Med 2000; 161:309.</a></li><li><a class="nounderline abstract_t">Burge PS, O'Brien IM, Harries MG. Peak flow rate records in the diagnosis of occupational asthma due to isocyanates. Thorax 1979; 34:317.</a></li><li><a class="nounderline abstract_t">Moscato G, Godnic-Cvar J, Maestrelli P. Statement on self-monitoring of peak expiratory flows in the investigation of occupational asthma. Subcommittee on Occupational Allergy of European Academy of Allergy and Clinical Immunology. J Allergy Clin Immunol 1995; 96:295.</a></li><li><a class="nounderline abstract_t">Park D, Moore VC, Burge CB, et al. Serial PEF measurement is superior to cross-shift change in diagnosing occupational asthma. Eur Respir J 2009; 34:574.</a></li><li><a class="nounderline abstract_t">Moore VC, Jaakkola MS, Burge CB, et al. Do long periods off work in peak expiratory flow monitoring improve the sensitivity of occupational asthma diagnosis? Occup Environ Med 2010; 67:562.</a></li><li><a class="nounderline abstract_t">Gannon PF, Newton DT, Belcher J, et al. Development of OASYS-2: a system for the analysis of serial measurement of peak expiratory flow in workers with suspected occupational asthma. Thorax 1996; 51:484.</a></li><li><a class="nounderline abstract_t">Fishwick D, Barraclough R, Pickering T, et al. Comparison of various airflow measurements in symptomatic textile workers. Occup Med (Lond) 2010; 60:631.</a></li><li><a class="nounderline abstract_t">Townsend MC. ACOEM position statement. Spirometry in the occupational setting. American College of Occupational and Environmental Medicine. J Occup Environ Med 2000; 42:228.</a></li><li><a class="nounderline abstract_t">Leroyer C, Perfetti L, Trudeau C, et al. Comparison of serial monitoring of peak expiratory flow and FEV1 in the diagnosis of occupational asthma. Am J Respir Crit Care Med 1998; 158:827.</a></li><li><a class="nounderline abstract_t">Burge PS. Occupational asthma due to soft soldering fluxes containing colophony (rosin, pine resin). Eur J Respir Dis Suppl 1982; 123:65.</a></li><li><a class="nounderline abstract_t">Bardy JD, Malo JL, Séguin P, et al. Occupational asthma and IgE sensitization in a pharmaceutical company processing psyllium. Am Rev Respir Dis 1987; 135:1033.</a></li><li><a class="nounderline abstract_t">Nicholson PJ, Cullinan P, Taylor AJ, et al. Evidence based guidelines for the prevention, identification, and management of occupational asthma. Occup Environ Med 2005; 62:290.</a></li><li><a class="nounderline abstract_t">Malo JL. Utilization of pulmonary function measurements in the assessment of occupational asthma. Curr Opin Allergy Clin Immunol 2002; 2:93.</a></li><li><a class="nounderline abstract_t">Girard F, Chaboillez S, Cartier A, et al. An effective strategy for diagnosing occupational asthma: use of induced sputum. Am J Respir Crit Care Med 2004; 170:845.</a></li><li><a class="nounderline abstract_t">Anees W, Huggins V, Pavord ID, et al. Occupational asthma due to low molecular weight agents: eosinophilic and non-eosinophilic variants. Thorax 2002; 57:231.</a></li><li><a class="nounderline abstract_t">Lemière C, Romeo P, Chaboillez S, et al. Airway inflammation and functional changes after exposure to different concentrations of isocyanates. J Allergy Clin Immunol 2002; 110:641.</a></li><li><a class="nounderline abstract_t">Racine G, Castano R, Cartier A, Lemiere C. Diagnostic Accuracy of Inflammatory Markers for Diagnosing Occupational Asthma. J Allergy Clin Immunol Pract 2017; 5:1371.</a></li><li><a class="nounderline abstract_t">Beretta C, Rifflart C, Evrard G, et al. Assessment of eosinophilic airway inflammation as a contribution to the diagnosis of occupational asthma. Allergy 2018; 73:206.</a></li><li><a class="nounderline abstract_t">Lemière C. Advanced diagnostic studies: exhaled breath and sputum analyses. J Occup Environ Med 2014; 56 Suppl 10:S45.</a></li><li><a class="nounderline abstract_t">Quirce S. Eosinophilic bronchitis in the workplace. Curr Opin Allergy Clin Immunol 2004; 4:87.</a></li><li><a class="nounderline abstract_t">Lemière C, Efthimiadis A, Hargreave FE. Occupational eosinophilic bronchitis without asthma: an unknown occupational airway disease. J Allergy Clin Immunol 1997; 100:852.</a></li><li><a class="nounderline abstract_t">Quirce S, Fernández-Nieto M, de Miguel J, Sastre J. Chronic cough due to latex-induced eosinophilic bronchitis. J Allergy Clin Immunol 2001; 108:143.</a></li><li><a class="nounderline abstract_t">Vandenplas O, D'Alpaos V, Heymans J, et al. Sputum eosinophilia: an early marker of bronchial response to occupational agents. Allergy 2009; 64:754.</a></li><li><a class="nounderline abstract_t">Obata H, Dittrick M, Chan H, Chan-Yeung M. Sputum eosinophils and exhaled nitric oxide during late asthmatic reaction in patients with western red cedar asthma. Eur Respir J 1999; 13:489.</a></li><li><a class="nounderline abstract_t">Lemière C, D'Alpaos V, Chaboillez S, et al. Investigation of occupational asthma: sputum cell counts or exhaled nitric oxide? Chest 2010; 137:617.</a></li><li><a class="nounderline abstract_t">Tossa P, Paris C, Zmirou-Navier D, et al. Increase in exhaled nitric oxide is associated with bronchial hyperresponsiveness among apprentices. Am J Respir Crit Care Med 2010; 182:738.</a></li><li><a class="nounderline abstract_t">Walters GI, Moore VC, McGrath EE, Burge S. Fractional exhaled nitric oxide in the interpretation of specific inhalational challenge tests for occupational asthma. Lung 2014; 192:119.</a></li><li><a class="nounderline abstract_t">Engel J, van Kampen V, Lotz A, et al. An increase of fractional exhaled nitric oxide after specific inhalation challenge is highly predictive of occupational asthma. Int Arch Occup Environ Health 2018; 91:799.</a></li><li><a class="nounderline abstract_t">Brannath W, Scharpenberg M, Schmidt S. Single-stage, three-arm, adaptive test strategies for non-inferiority trials with an unstable reference. Stat Med 2022; 41:5033.</a></li><li><a class="nounderline abstract_t">Piipari R, Piirilä P, Keskinen H, et al. Exhaled nitric oxide in specific challenge tests to assess occupational asthma. Eur Respir J 2002; 20:1532.</a></li><li><a class="nounderline abstract_t">Lemiere C, NGuyen S, Sava F, et al. Occupational asthma phenotypes identified by increased fractional exhaled nitric oxide after exposure to causal agents. J Allergy Clin Immunol 2014; 134:1063.</a></li><li><a class="nounderline abstract_t">Betancor D, Villalobos V, Valverde-Monge M, et al. Exhaled nitric oxide is of limited value in the diagnosis of occupational asthma. J Allergy Clin Immunol Pract 2021; 9:1726.</a></li><li><a class="nounderline abstract_t">Lemiere C, Miedinger D, Jacob V, et al. Comparison of methacholine and mannitol bronchial provocation tests in workers with occupational asthma. J Allergy Clin Immunol 2012; 129:555.</a></li><li><a class="nounderline abstract_t">Dehaut P, Rachiele A, Martin RR, Malo JL. Histamine dose-response curves in asthma: reproducibility and sensitivity of different indices to assess response. Thorax 1983; 38:516.</a></li><li><a class="nounderline abstract_t">Pralong JA, Lemière C, Rochat T, et al. Predictive value of nonspecific bronchial responsiveness in occupational asthma. J Allergy Clin Immunol 2016; 137:412.</a></li><li><a class="nounderline abstract_t">Mapp CE, Dal Vecchio L, Boschetto P, et al. Toluene diisocyanate-induced asthma without airway hyperresponsiveness. Eur J Respir Dis 1986; 68:89.</a></li><li><a class="nounderline abstract_t">Sastre J, Fernández-Nieto M, Novalbos A, et al. Need for monitoring nonspecific bronchial hyperresponsiveness before and after isocyanate inhalation challenge. Chest 2003; 123:1276.</a></li><li><a class="nounderline abstract_t">Vandenplas O, Delwiche JP, Jamart J, Van de Weyer R. Increase in non-specific bronchial hyperresponsiveness as an early marker of bronchial response to occupational agents during specific inhalation challenges. Thorax 1996; 51:472.</a></li><li><a class="nounderline abstract_t">Lemière C, Chaboillez S, Malo JL, Cartier A. Changes in sputum cell counts after exposure to occupational agents: what do they mean? J Allergy Clin Immunol 2001; 107:1063.</a></li><li class="breakAll">American Thoracic Society. Selected specialized clinical tests in environmental, occupational, and population health. http://www.thoracic.org/professionals/clinical-resources/environmental-and-occupational/clinical-tests.php (Accessed on August 03, 2017).</li><li><a class="nounderline abstract_t">Suojalehto H, Cullinan P, European Respiratory Society Task Force on Specific Inhalation Challenges with Occupational Agents. Specific inhalation challenge tests for occupational asthma in Europe: a survey. Eur Respir Rev 2014; 23:266.</a></li><li class="breakAll">American Thoracic Society. Selected Specialized Clinical Tests In EOH Evaluation. http://www.thoracic.org/professionals/clinical-resources/environmental-and-occupational/clinical-tests.php (Accessed on January 29, 2019).</li><li><a class="nounderline abstract_t">Rioux JP, Malo JL, L'Archevêque J, et al. Workplace-specific challenges as a contribution to the diagnosis of occupational asthma. Eur Respir J 2008; 32:997.</a></li><li><a class="nounderline abstract_t">Vandenplas O, Malo JL. Inhalation challenges with agents causing occupational asthma. Eur Respir J 1997; 10:2612.</a></li><li><a class="nounderline abstract_t">Vandenplas O, Suojalehto H, Aasen TB, et al. Specific inhalation challenge in the diagnosis of occupational asthma: consensus statement. Eur Respir J 2014; 43:1573.</a></li><li><a class="nounderline abstract_t">Tarlo SM. The role and interpretation of specific inhalation challenges in the diagnosis of occupational asthma. Can Respir J 2015; 22:322.</a></li><li class="breakAll">Vandenplas O, Burge PS, Moscato G, Malo JL. Functional assessment. In: Asthma in the workplace, 4th ed, Malo JL, Chan-Yeung M, Bernstein DI (Eds), CRC Press, Boca Raton, FL 2012. p.113-132.</li><li><a class="nounderline abstract_t">Vandenplas O, D'Alpaos V, Evrard G, Jamart J. Incidence of severe asthmatic reactions after challenge exposure to occupational agents. Chest 2013; 143:1261.</a></li><li><a class="nounderline abstract_t">Tarlo SM, Lemiere C. Occupational asthma. N Engl J Med 2014; 370:640.</a></li><li><a class="nounderline abstract_t">Ojanguren I, Moullec G, Hobeika J, et al. Clinical and inflammatory characteristics of Asthma-COPD overlap in workers with occupational asthma. PLoS One 2018; 13:e0193144.</a></li><li><a class="nounderline abstract_t">Tarlo SM, Quirce S. Impact of Identification of Clinical Phenotypes in Occupational Asthma. J Allergy Clin Immunol Pract 2020; 8:3277.</a></li><li><a class="nounderline abstract_t">Hoy RF, Ribeiro M, Anderson J, Tarlo SM. Work-associated irritable larynx syndrome. Occup Med (Lond) 2010; 60:546.</a></li><li><a class="nounderline abstract_t">Tonini S, Dellabianca A, Costa C, et al. Irritant vocal cord dysfunction and occupational bronchial asthma: differential diagnosis in a health care worker. Int J Occup Med Environ Health 2009; 22:401.</a></li><li><a class="nounderline abstract_t">Thomas M, McKinley RK, Freeman E, Foy C. Prevalence of dysfunctional breathing in patients treated for asthma in primary care: cross sectional survey. BMJ 2001; 322:1098.</a></li><li><a class="nounderline abstract_t">van Rooy FG, Rooyackers JM, Prokop M, et al. Bronchiolitis obliterans syndrome in chemical workers producing diacetyl for food flavorings. Am J Respir Crit Care Med 2007; 176:498.</a></li><li><a class="nounderline abstract_t">King TE Jr. Miscellaneous causes of bronchiolitis: inhalational, infectious, drug-induced, and idiopathic. Semin Respir Crit Care Med 2003; 24:567.</a></li></ol></div><div id="topicVersionRevision">Topic 550 Version 30.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Tarlo S, Vandenplas O, Bernstein DI, Malo JL. Definition and classification of asthma in the workplace. In: Asthma in the workplace, 5th, Tarlo S, Bernstein DI, Malo JL, Vandenplas O (Eds), CRC Press, Boca Raton, FL 2022. p.3.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30320613" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Occupational asthma: clinical phenotypes, biomarkers, and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29956349" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Are high- and low-molecular-weight sensitizing agents associated with different clinical phenotypes of occupational asthma?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11488324" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Natural history of sensitization, symptoms and occupational diseases in apprentices exposed to laboratory animals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9230239" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Prevalence and intensity of rhinoconjunctivitis in subjects with occupational asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11069559" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Epidemiology of occupational rhinitis: prevalence, aetiology and determinants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18835961" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Occupational rhinitis in workers investigated for occupational asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16319335" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : What are the questionnaire items most useful in identifying subjects with occupational asthma?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16343088" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Occupational asthma in apprentice adolescent car painters.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20717691" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Occupational asthma caused by triglycidyl isocyanurate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20427586" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Skin exposure and asthma: is there a connection?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17431479" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Skin exposure to isocyanates: reasons for concern.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18317018" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Lung/skin connections in occupational lung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6656021" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : [Asthma due to hard alloy dusts--a case of allergic bronchial asthma and contact dermatitis due to metallic cobalt].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19433617" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Cutaneous and respiratory symptoms among professional cleaners.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16890771" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Natural rubber latex allergy among health care workers: a systematic review of the evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22238032" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Occupational contact allergens: are they also associated with occupational asthma?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21199406" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Correlation between acoustic rhinometry and subjective nasal patency during nasal challenge test in subjects with suspected occupational rhinitis; a prospective controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19281900" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Occupational asthma: current concepts in pathogenesis, diagnosis, and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18779187" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Diagnosis and management of work-related asthma: American College Of Chest Physicians Consensus Statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31149852" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : The Occupational Burden of Nonmalignant Respiratory Diseases. An Official American Thoracic Society and European Respiratory Society Statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35314486" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : British Thoracic Society Clinical Statement on occupational asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10711281" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Performance of population specific job exposure matrices (JEMs): European collaborative analyses on occupational risk factors for chronic obstructive pulmonary disease with job exposure matrices (ECOJEM).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33332925" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : New causes of immunologic occupational asthma 2014-2020.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2001062" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Is the clinical history a satisfactory means of diagnosing occupational asthma?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9438044" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Relation between occupational asthma case history, bronchial methacholine challenge, and specific challenge test in patients with suspected occupational asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11240958" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Occupational asthma in symptomatic workers exposed to natural rubber latex: evaluation of diagnostic procedures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18805880" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Performance of self-reported occupational exposure compared to a job-exposure matrix approach in asthma and chronic rhinitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25369880" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Occupational anaphylaxis--an EAACI task force consensus statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12110815" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Material safety data sheets: are they reliable in identifying human hazards?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12110815" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Material safety data sheets: are they reliable in identifying human hazards?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23058644" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Work-exacerbated asthma and occupational asthma: do they really differ?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16314332" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Future advances in work-related asthma and the impact on occupational health.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12358347" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Asthma characteristics in cleaning workers, workers in other risk jobs and office workers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1460199" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Natural history of occupational asthma: relevance of type of agent and other factors in the rate of development of symptoms in affected subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21738881" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Occupational asthma: etiologies and risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3814545" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Does atopy have any predictive value for laboratory animal allergy? A comparison of different concepts of atopy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23409759" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : EAACI position paper: skin prick testing in the diagnosis of occupational type I allergies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30804164" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Performance of specific immunoglobulin E tests for diagnosing occupational asthma: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28862493" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : An Official American Thoracic Society Workshop Report: Presentations and Discussion of the Sixth Jack Pepys Workshop on Asthma in the Workplace.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26940537" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : The role of allergen components for the diagnosis of latex-induced occupational asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29445888" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Addressing Molecular Diagnosis of Occupational Allergies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37186333" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : EAACI Molecular Allergology User's Guide 2.0.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24735032" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Official American Thoracic Society technical standards: spirometry in the occupational setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28163029" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Airway Hyperresponsiveness in Asthma: Measurement and Clinical Relevance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10619836" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Guidelines for methacholine and exercise challenge testing-1999. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/225841" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Peak flow rate records in the diagnosis of occupational asthma due to isocyanates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7560631" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Statement on self-monitoring of peak expiratory flows in the investigation of occupational asthma. Subcommittee on Occupational Allergy of European Academy of Allergy and Clinical Immunology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19324953" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Serial PEF measurement is superior to cross-shift change in diagnosing occupational asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20439321" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Do long periods off work in peak expiratory flow monitoring improve the sensitivity of occupational asthma diagnosis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8711675" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Development of OASYS-2: a system for the analysis of serial measurement of peak expiratory flow in workers with suspected occupational asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20844055" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Comparison of various airflow measurements in symptomatic textile workers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10738702" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : ACOEM position statement. Spirometry in the occupational setting. American College of Occupational and Environmental Medicine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9731012" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Comparison of serial monitoring of peak expiratory flow and FEV1 in the diagnosis of occupational asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6962084" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Occupational asthma due to soft soldering fluxes containing colophony (rosin, pine resin).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3579003" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Occupational asthma and IgE sensitization in a pharmaceutical company processing psyllium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15837849" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Evidence based guidelines for the prevention, identification, and management of occupational asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11964755" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Utilization of pulmonary function measurements in the assessment of occupational asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15271693" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : An effective strategy for diagnosing occupational asthma: use of induced sputum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11867827" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Occupational asthma due to low molecular weight agents: eosinophilic and non-eosinophilic variants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12373274" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Airway inflammation and functional changes after exposure to different concentrations of isocyanates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28286155" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Diagnostic Accuracy of Inflammatory Markers for Diagnosing Occupational Asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28771844" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Assessment of eosinophilic airway inflammation as a contribution to the diagnosis of occupational asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25285976" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Advanced diagnostic studies: exhaled breath and sputum analyses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15021059" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Eosinophilic bronchitis in the workplace.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9438499" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Occupational eosinophilic bronchitis without asthma: an unknown occupational airway disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11447398" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Chronic cough due to latex-induced eosinophilic bronchitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19220213" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Sputum eosinophilia: an early marker of bronchial response to occupational agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10232414" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Sputum eosinophils and exhaled nitric oxide during late asthmatic reaction in patients with western red cedar asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19952060" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Investigation of occupational asthma: sputum cell counts or exhaled nitric oxide?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20508219" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Increase in exhaled nitric oxide is associated with bronchial hyperresponsiveness among apprentices.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24232978" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Fractional exhaled nitric oxide in the interpretation of specific inhalational challenge tests for occupational asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29850946" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : An increase of fractional exhaled nitric oxide after specific inhalation challenge is highly predictive of occupational asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35979723" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Single-stage, three-arm, adaptive test strategies for non-inferiority trials with an unstable reference.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12503715" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Exhaled nitric oxide in specific challenge tests to assess occupational asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25262466" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Occupational asthma phenotypes identified by increased fractional exhaled nitric oxide after exposure to causal agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33242627" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Exhaled nitric oxide is of limited value in the diagnosis of occupational asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22019089" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Comparison of methacholine and mannitol bronchial provocation tests in workers with occupational asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6612637" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Histamine dose-response curves in asthma: reproducibility and sensitivity of different indices to assess response.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26220529" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Predictive value of nonspecific bronchial responsiveness in occupational asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3009212" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Toluene diisocyanate-induced asthma without airway hyperresponsiveness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12684321" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Need for monitoring nonspecific bronchial hyperresponsiveness before and after isocyanate inhalation challenge.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8711673" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Increase in non-specific bronchial hyperresponsiveness as an early marker of bronchial response to occupational agents during specific inhalation challenges.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11398086" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Changes in sputum cell counts after exposure to occupational agents: what do they mean?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11398086" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Changes in sputum cell counts after exposure to occupational agents: what do they mean?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24881084" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Specific inhalation challenge tests for occupational asthma in Europe: a survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24881084" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Specific inhalation challenge tests for occupational asthma in Europe: a survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18508825" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Workplace-specific challenges as a contribution to the diagnosis of occupational asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9426105" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Inhalation challenges with agents causing occupational asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24603815" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Specific inhalation challenge in the diagnosis of occupational asthma: consensus statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26641806" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : The role and interpretation of specific inhalation challenges in the diagnosis of occupational asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26641806" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : The role and interpretation of specific inhalation challenges in the diagnosis of occupational asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23117442" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Incidence of severe asthmatic reactions after challenge exposure to occupational agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24521110" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Occupational asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29499062" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Clinical and inflammatory characteristics of Asthma-COPD overlap in workers with occupational asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32561498" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Impact of Identification of Clinical Phenotypes in Occupational Asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20871021" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Work-associated irritable larynx syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20053620" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Irritant vocal cord dysfunction and occupational bronchial asthma: differential diagnosis in a health care worker.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11337441" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Prevalence of dysfunctional breathing in patients treated for asthma in primary care: cross sectional survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17541015" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Bronchiolitis obliterans syndrome in chemical workers producing diacetyl for food flavorings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16088573" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Miscellaneous causes of bronchiolitis: inhalational, infectious, drug-induced, and idiopathic.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
